Novo Nordisk has partnered with Indian pharma firm Emcure to introduce a new weight-loss medication, Poviztra, to the Indian market. This move comes as demand for anti-obesity drugs continues to rise, following closely on the heels of similar product launches by major global players.
Novo Nordisk is strengthening its foothold in the Indian obesity treatment market by teaming up with Emcure to exclusively distribute and market Poviztra, a 2.4 mg semaglutide injection. This product is a rebranded version of its global hit Wegovy, designed to cater specifically to Indian consumers. Poviztra will be available under a new identity, widening access across the country.
The launch of Poviztra comes only months after Wegovy made its Indian debut in June. That rollout followed Eli Lilly’s introduction of its own weight-loss drug Mounjaro, marking growing competition in this segment.
The 2.4 mg dose of Wegovy is priced at ₹26,015 for 1 month. Although Poviztra’s pricing has not been revealed, it is expected to target a similar demographic looking for long-term weight management solutions.
Emcure will be responsible for ensuring the drug reaches a broad range of patients in India. Novo Nordisk highlighted that this initiative aligns with its mission to improve access to innovative therapies across emerging markets. The collaboration is expected to optimise the reach and impact of semaglutide treatments in India’s growing anti-obesity segment.
Read More: Glenmark Pharma Expands US Portfolio with New Acid Regulation Injection!
India’s healthcare sector is witnessing a surge in demand for weight-loss therapies, fuelled by lifestyle changes and rising obesity rates. Pharmaceutical companies are capitalising on this opportunity with strategic alliances. Poviztra is poised to contribute significantly to this evolving landscape, building upon Novo Nordisk’s global success.
On November 10, 2025, Emcure Pharmaceuticals share price opened at ₹1,362.40 on NSE, near the previous close of ₹1,362.40. During the day, it surged to ₹1,463.70 and dipped to ₹1,362.40. The stock is trading at ₹1,429.10 as of 2:33 PM. The stock registered a significant gain of 4.90%.
Over the past week, it has moved up by 7.78%, over the past month, it has moved up by 2.39%, and over the past 3 months, it has moved up by 3.03%.
Novo Nordisk’s partnership with Emcure marks a key development in India’s weight-loss treatment sector. With Poviztra, the companies aim to expand the reach of semaglutide-based therapy to a wider patient base while intensifying the competition among global drugmakers operating in India.
Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in securities are subject to market risks. Read all related documents carefully before investing.
Published on: Nov 10, 2025, 5:32 PM IST
Team Angel One
We're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
